Blog

IVIG

What Is SCIG?

doctor holding vial if scig immunoglobulin

Subcutaneous immune globulin (SCIG) is a type of immunoglobulin therapy used to strengthen the immune system of patients with immunodeficiency disorders or patients whose body does not make enough immunoglobulins (antibodies). This therapy has recently gained popularity and is considered a promising and effective treatment option due to its convenience, efficacy, and reduced risk of systemic side effects compared to intravenous immune globulin (IVIG) therapy

Nói chuyện với một chuyên gia

Về Trợ cấp đồng thanh toán
(877) 778-0318

The aim of this article is to provide a comprehensive guide for patients who are about to experience SCIG treatment and are curious about what to expect and its benefits.  By the end of this article, you will gain an understanding of what SCIG is, how it differs from IVIG, its potential benefits, associated risks, and the conditions for which it is typically recommended.

What Is Subcutaneous Immune Globulin?

In SCIG therapy, a patient receives a solution containing a purified form of antibodies (consisting of 97-98% of IgG and a small ratio of IgM and IgA) extracted from the healthy donor’s blood. These antibodies are the essential components of our immune system and play a vital role in fighting off infections and diseases. SCIG offers an effective way to manage various medical conditions ranging from immunodeficiencies to autoimmune diseases. 

How Is It Given?

SCIG is administered subcutaneously, meaning it is given as a subcutaneous injection under the skin, specifically in the deepest layer of the skin. The common subcutaneous injection sites include the upper arms, thighs, and abdomen. 

The administration procedure of SCIG is easy to learn, and teenagers or elderly patients can easily inject themselves at home after receiving proper training from their healthcare providers.   

How SCIG Differs From IVIG

SCIG and IVIG are both forms of immunotherapy used to strengthen the immune system but differ in several aspects. For instance, IVIG is administered intravenously, where the immunoglobulin solution is directly infused into the bloodstream through a vein, while SCIG is injected under the skin. 

Furthermore, the administration frequency also varies between SCIG and IVIG therapy. IVIG is usually administered less frequently, typically once every few weeks or even once a month, as the higher concentration of antibodies in the intravenous infusion lasts longer in the bloodstream. 

On the other hand, SCIG is typically given more frequently, often on a weekly or bi-weekly basis, as the slow absorption of antibodies requires more frequent doses to maintain adequate levels in the body.

Potential Benefits of Subcutaneous Immune Globulin Therapy

SCIG therapy offers several benefits, making it a valuable treatment option for patients with various medical conditions. Some of the key advantages of receiving SCIG therapy are as follows:

Convenience and Flexibility

One of the major advantages of SCIG therapy is the convenience it offers to patients. Instead of spending hours at a hospital or clinic for IV infusions, you can self-administer at home, thereby reducing the disruption to your daily life.

Reduced Risks of Systemic Side Effects

SCIG has been shown to have a lower risk of systemic side effects like headaches, fever, or chills compared to IVIG. When administered subcutaneously, the slow and gradual absorption of antibodies allows the body to adapt more comfortably to the treatment, resulting in fewer immediate reactions and a more stable immune response.

Enhanced Quality of Life

Due to the self-administration option and fewer systemic side effects, individuals undergoing SCIG therapy reported improved quality of life. They were able to participate in daily activities without the burden of frequent hospital visits.

Control Over Treatment Timing

With SCIG, patients have the flexibility to choose the timing of their treatments, allowing them to adjust the schedule as needed to accommodate personal commitments or other medical treatments.

Less Intrusive Procedure

SCIG administration involves a small subcutaneous injection, which is generally less intrusive and more tolerable for patients compared to intravenous infusions.

Can SCIG help?

Free Treatment Info
Consult a Specialist

Risks and Complications Associated With SCIG

Like any other treatment, SCIG therapy also has some risks and complications. 

Local Injection Site Reactions

Some patients may experience mild reactions at the injection site, such as redness, swelling, or itching. These reactions are usually temporary and subside on their own after 24 – 48 hours.

Systemic Side Effects

Although less common than IVIG, some patients might still experience mild systemic side effects, such as fatigue or muscle aches. However, these side effects generally diminish with time.

Infections

As with any medical procedure involving needles, there is a minimal risk of infection. However, following proper hygiene and sterile techniques during administration can significantly reduce this risk.

In What Cases Is SCIG Recommended?

A woman preparing to give herself an SCIG injection

SCIG is generally recommended when a patient has the following conditions:

Primary Immunodeficiency Diseases

SCIG is commonly recommended for individuals with primary immunodeficiency diseases with antibody deficiency like XLA or agammaglobulinemia. In these conditions, the immune system becomes impaired and leads to recurrent infections. SCIG helps boost their immune response and reduce the frequency of infections.

Neurological Disorders

Some neurological disorders can benefit from SCIG therapy, as it can help modulate the immune response, reduce inflammation, and potentially slow down the progression of certain conditions.

Inflammatory Conditions

SCIG is approved to treat inflammatory disorders like Viêm đa dây thần kinh mất myelin mạn tính (CIDP). This condition occurs due to excessive immune responses and can be managed effectively with SCIG therapy,  which offers relief and better disease control.

Precautions To Follow Prior to SCIG Therapy

Before undergoing therapy, certain precautions should be taken to ensure a safe and effective treatment experience.

  • Inform your healthcare provider if you have any medication or Ig product allergies.
  • Discuss the risks or benefits of SCIG therapy with your healthcare provider if you are pregnant or planning to breastfeed.
  • Inform your healthcare provider if you are taking any medication or vaccination, as medications may interfere with treatment. 

Get Financial Assistance for SCIG

(877) 778-0318

Câu hỏi thường gặp

Can I self-administer SCIG therapy at home?

Yes, with proper training and guidance from healthcare professionals, you can self-administer this therapy in the comfort of your home.

Are there any long-term risks?

Long-term risks of therapy are generally minimal. Regular monitoring and follow-up with your healthcare providers can help identify and address any potential concerns.

Is SCIG suitable for children?

Yes, it can be used in children with certain medical conditions. Pediatric patients may require adjustments in dosing and administration based on their age and weight.

How effective is SCIG in treating immunodeficiency disorders?

SCIG has proven to be highly effective in managing immunodeficiency disorders, reducing the frequency of infections, and improving overall immune function. 

Is this therapy as effective as IVIG?

Yes, studies have demonstrated that SCIG is as effective as IVIG for most immunodeficiency and immunomodulatory conditions.  

Is it safe?

Yes, SCIG is considered a safe product as it is made from blood with a low risk of containing agents that cause diseases such as AIDS (HIV), hepatitis B, hepatitis C, and variant Creutzfeld-Jacob disease (vCJD), also known as “mad cow disease.” 

The blood donors undergo extensive testing to ensure their blood is safe for use. In addition, it is treated to eliminate any viruses that could cause AIDS (HIV), hepatitis B, or hepatitis C.

TÀI LIỆU THAM KHẢO:

  1. Kobrynski, L. (2012). Subcutaneous immunoglobulin therapy: A new option for patients with primary immunodeficiency diseases. Biologics: Targets & Therapy, 6, 277-287. https://doi.org/10.2147/BTT.S25188
  2. Misbah, S., Sturzenegger, M. H., Borte, M., Shapiro, R. S., Wasserman, R. L., Berger, M., & Ochs, H. D. (2009). Subcutaneous immunoglobulin: Opportunities and outlook. Clinical and Experimental Immunology, 158(Suppl 1), 51-59. https://doi.org/10.1111/j.1365-2249.2009.04027.x
  3. Moore, M. L., & Quinn, J. M. (2008). Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: Advancements into the 21st century. Annals of Allergy, Asthma & Immunology, 101(2), 114-121. https://doi.org/10.1016/S1081-1206(10)60197-4
  4. Epland, K., Suez, D., & Paris, K. (2022). A clinician’s guide for the administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol, 18(1). https://doi.org/10.1186/s13223-022-00726
Thông tin này không thay thế cho lời khuyên hoặc phương pháp điều trị y tế. Hãy trao đổi với bác sĩ hoặc nhà cung cấp dịch vụ chăm sóc sức khỏe về tình trạng sức khỏe của bạn trước khi bắt đầu bất kỳ phương pháp điều trị mới nào. AmeriPharma® Specialty Care không chịu bất kỳ trách nhiệm nào đối với thông tin được cung cấp hoặc đối với bất kỳ chẩn đoán hoặc phương pháp điều trị nào được đưa ra do thông tin này, cũng như không chịu trách nhiệm về độ tin cậy của nội dung. AmeriPharma® Specialty Care không vận hành tất cả các trang web/tổ chức được liệt kê ở đây, cũng không chịu trách nhiệm về tính khả dụng hoặc độ tin cậy của nội dung của họ. Các danh sách này không ngụ ý hoặc cấu thành sự chứng thực, tài trợ hoặc khuyến nghị của AmeriPharma® Specialty Care. Trang web này có thể chứa các tham chiếu đến các loại thuốc theo toa có tên thương hiệu là nhãn hiệu hoặc nhãn hiệu đã đăng ký của các nhà sản xuất dược phẩm không liên kết với AmeriPharma® Specialty Care.
ĐÃ ĐƯỢC XEM XÉT Y KHOA BỞI Tiến sĩ Saba Rassouli, Tiến sĩ Dược

Tiến sĩ Saba Rassouli, Tiến sĩ Dược sinh ra và lớn lên tại Iran. Cô đã nhận bằng dược sĩ của Đại học Marshall B. Ketchum vào năm 2022, nơi cô tốt nghiệp loại xuất sắc. Phần bổ ích nhất trong công việc của cô là có cơ hội chăm sóc từng bệnh nhân như thể họ là gia đình và lắng nghe họ nói về mức độ hạnh phúc và hài lòng của họ với các dịch vụ do AmeriPharma cung cấp. Trong thời gian rảnh rỗi, cô thích đi dạo, đọc sách và thử các nhà hàng và món ăn khác nhau.

Liên hệ với chúng tôi

Sử dụng mẫu đơn tuân thủ HIPAA bên dưới để yêu cầu nạp lại đơn thuốc của bạn. Nếu bạn có bất kỳ câu hỏi nào về thuốc của mình hoặc cách sử dụng thuốc, vui lòng truy cập trang Liên hệ với chúng tôi hoặc gọi cho chúng tôi theo số (877) 778-0318.

HIPAA Compliant

Bằng cách gửi, bạn đồng ý với AmeriPharma Điều khoản sử dụng, Chính sách bảo mật, Và Thông báo về Thực hành Bảo mật

viVietnamese